文献速递糖尿病

从每日基础胰岛素转换为每周一次胰岛素icodec的长期2型糖尿病胰岛素使用者的CGM指标与低血糖持续时间:ONWARDS 2和ONWARDS 4的事后分析

Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
PubMed 文献 · Diabetes Care · 2024-01-01

本事后分析基于两项26周3a期试验(ONWARDS 2和ONWARDS 4),评估有胰岛素使用经验的长期2型糖尿病患者从每日基础胰岛素转换为每周一次胰岛素icodec后,CGM指标及低血糖持续时间的变化。结果显示,在所有CGM时间段内,icodec与对照组的TIR、TAR及TBR(<3.0 mmol/L)均无统计学显著差异,低血糖持续时间(<3.9 mmol/L)中位数≤40分钟,TBR保持在推荐目标内。

要点

  • 在ONWARDS 2和ONWARDS 4所有CGM时间段内,icodec与对照组的TIR、TAR及TBR(<3.0 mmol/L)均无统计学显著差异。
  • 治疗结束时,ONWARDS 2平均TIR为icodec 63.1% vs 德谷胰岛素59.5%;ONWARDS 4为icodec 66.9% vs 甘精胰岛素U100 66.4%。
  • 各时间段及治疗组TBR <3.9 mmol/L和<3.0 mmol/L均保持在推荐目标内(分别<4%和<1%),低血糖持续时间中位数≤40分钟。

核心结论

  • 在有胰岛素使用经验的长期2型糖尿病患者中,icodec与每日基础胰岛素类似物在所有时间段内的CGM-based TIR、TAR及CGM-derived低血糖持续时间(<3.9 mmol/L)相当,TBR保持在推荐目标内。

研究设计与样本

  • 两项26周3a期试验(ONWARDS 2和ONWARDS 4)的事后分析,纳入有胰岛素使用经验的长期2型糖尿病患者。
  • ONWARDS 2比较icodec与德谷胰岛素(基础方案),ONWARDS 4比较icodec与甘精胰岛素U100(基础-餐时方案),使用双盲CGM数据。
  • 评估三个CGM时间段:转换期(第0-4周)、治疗结束期(第22-26周)和随访期(第27-31周)。

主要发现

  • 在所有时间段内,icodec与对照组的TIR、TAR及TBR(<3.0 mmol/L)均无统计学显著差异。
  • 治疗结束期,ONWARDS 2平均TIR为icodec 63.1% vs 德谷胰岛素59.5%;ONWARDS 4为icodec 66.9% vs 甘精胰岛素U100 66.4%。
  • 各时间段及治疗组TBR <3.9 mmol/L和<3.0 mmol/L均保持在推荐目标内(分别<4%和<1%)。
  • 低血糖持续时间(<3.9 mmol/L)在各时间段及治疗组间相当,中位数≤40分钟。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This post hoc analysis assessed continuous glucose monitoring (CGM)-based metrics and hypoglycemia duration with once-weekly insulin icodec versus once-daily basal insulin analogs in insulin-experienced individuals with long-standing type 2 diabetes from two 26-week phase 3a trials (ONWARDS 2 and ONWARDS 4). RESEARCH DESIGN AND METHODS: Time in range (TIR) (3.9-10.0 mmol/L), time above range (TAR) (>10.0 mmol/L), and time below range (TBR) (<3.9 mmol/L and <3.0 mmol/L) were assessed during three CGM time periods (switch [weeks 0-4], end of treatment [weeks 22-26], and follow-up [weeks 27-31]) for icodec versus comparators (ONWARDS 2, insulin degludec [basal regimen]; ONWARDS 4, insulin glargine U100 [basal-bolus regimen]) using double-blind CGM data. CGM-derived hypoglycemic episode duration (<3.9 mmol/L) was assessed. RESULTS: In both trials, there were no statistically significant differences in TIR, TAR, or TBR (<3.0 mmol/L) for icodec versus comparators across all time periods. In the end-of-treatment period, mean TIR was 63.1% (icodec) vs. 59.5% (degludec) in ONWARDS 2 and 66.9% (icodec) vs. 66.4% (glargine U100) in ONWARDS 4. Mean TBR <3.9 mmol/L and <3.0 mmol/L remained within recommended targets (<4% and <1%, respectively) across time periods and treatment arms. Hypoglycemic episode duration (<3.9 mmol/L) was comparable across time periods and treatment arms (median duration ≤40 min). CONCLUSIONS: In insulin-experienced participants with long-standing type 2 diabetes, CGM-based TIR, TAR, and CGM-derived hypoglycemia duration (<3.9 mmol/L) were comparable for icodec and once-daily basal insulin analogs during all time periods. TBR remained within recommended targets.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bajaj HS, Ásbjörnsdóttir B, Carstensen L, et al. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes Care. 2024. PMID: 38380954. doi:10.2337/dc23-2136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。